Security
Verastem, Inc. Common Stock · VSTM
VSTMNASDAQCommon stockCurrentCIK 1526119Updated Nov 22, 2026
VSTM price & chart
Loading TradingView…
NASDAQ:VSTM on TradingView ↗About the company
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
In the news
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G - filed by STATE STREET CORP regarding Verastem, Inc.
S-3ASR filing
S-8 filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
10-Q filing
Other Events
Items 8.01, 9.01
424B5 filing
424B5 filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 2.02, 5.02, 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 176,852,000Source | 126,378,000Source | 206,511,000Source | 196,264,000Source | — | 227,808,000Source | 131,698,000Source | 123,539,000Source | 246,442,000Source | 101,538,000Source | 149,718,000Source | 95,050,000Source |
| Property, Plant and EquipmentUSD | 20,000Source | 39,000Source | — | 21,000Source | — | — | 22,000Source | 52,000Source | — | 32,000Source | 37,000Source | 92,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 137,706,000Source | 113,175,000Source | 136,353,000Source | 164,322,000Source | — | 165,551,000Source | 117,569,000Source | 81,316,000Source | 204,990,000Source | 88,818,000Source | 77,909,000Source | 74,933,000Source |
| Accounts Receivable | —Source | — | —Source | —Source | — | —Source | — | — | —Source | — | — | —Source |
| Inventory, NetUSD | 1,794,000Source | — | 2,396,000Source | 1,168,000Source | — | 2,287,000Source | — | — | 1,833,000Source | — | — | — |
| Assets, CurrentUSD | 154,056,000Source | 120,662,000Source | 176,155,000Source | 174,273,000Source | — | 202,904,000Source | 124,699,000Source | 117,674,000Source | 223,413,000Source | 94,961,000Source | 143,682,000Source | 92,870,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,640,000Source | 7,287,000Source | 8,332,000Source | 6,507,000Source | — | 8,581,000Source | 6,930,000Source | 7,323,000Source | 7,577,000Source | 5,943,000Source | 6,553,000Source | 4,945,000Source |
| Operating Lease, Right-of-Use AssetUSD | 730,000Source | 625,000Source | 2,625,000Source | 963,000Source | — | 2,793,000Source | 1,188,000Source | 997,000Source | 491,000Source | 1,405,000Source | 1,171,000Source | 1,789,000Source |
| Other Assets, NoncurrentUSD | 5,341,000Source | 5,052,000Source | 11,623,000Source | 5,371,000Source | — | 5,724,000Source | 5,548,000Source | 4,575,000Source | 6,112,000Source | 4,899,000Source | 4,587,000Source | 58,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 192,378,000Source | 94,159,000Source | 156,525,000Source | 160,208,000Source | — | 146,031,000Source | 164,131,000Source | 77,318,000Source | 189,245,000Source | 130,431,000Source | 71,185,000Source | 47,659,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 4,000Source | 9,000Source | 6,000Source | — | 9,000Source | 5,000Source | 3,000Source | 8,000Source | 4,000Source | 3,000Source | 20,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,132,082,000Source | -890,976,000Source | -1,236,262,000Source | -1,033,564,000Source | — | -1,201,589,000Source | -1,007,630,000Source | -858,753,000Source | -1,164,998,000Source | -955,527,000Source | -824,890,000Source | -737,523,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,545,000Source | — | 8,043,000Source | 5,290,000Source | — | 8,618,000Source | 6,639,000Source | -4,000Source | 5,229,000Source | — | 13,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -15,526,000Source | 11,060,000Source | 49,986,000Source | 36,056,000Source | 18,851,000Source | 81,777,000Source | -32,433,000Source | 25,062,000Source | 57,197,000Source | -28,893,000Source | 57,374,000Source | 47,391,000Source |
| Additional Paid in Capital, Common StockUSD | 1,114,004,000Source | 902,032,000Source | 1,278,196,000Source | 1,064,324,000Source | — | 1,274,739,000Source | 968,553,000Source | 883,816,000Source | 1,216,958,000Source | 926,630,000Source | 882,248,000Source | 784,894,000Source |
| Liabilities and EquityUSD | 176,852,000Source | 126,378,000Source | 206,511,000Source | 196,264,000Source | — | 227,808,000Source | 131,698,000Source | 123,539,000Source | 246,442,000Source | 101,538,000Source | 149,718,000Source | 95,050,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 59,712,000Source | 37,374,000Source | 78,130,000Source | 50,361,000Source | — | 66,845,000Source | 35,619,000Source | 26,725,000Source | 72,268,000Source | 30,973,000Source | 26,380,000Source | 21,663,000Source |
| Operating Lease, Liability, CurrentUSD | 793,000Source | 780,000Source | 493,000Source | 1,044,000Source | — | 494,000Source | 1,019,000Source | 981,000Source | 535,000Source | 995,000Source | 941,000Source | 794,000Source |
| Accounts Payable, CurrentUSD | 9,888,000Source | 4,438,000Source | 17,999,000Source | 8,047,000Source | — | 9,602,000Source | 7,199,000Source | 7,449,000Source | 12,448,000Source | 4,026,000Source | 7,184,000Source | 4,901,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 2,121,000Source | — | — | 2,316,000Source | 271,000Source | 270,000Source | — | 535,000Source | 530,000Source | 1,470,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 44,721,000Source | 22,153,000Source | 54,196,000Source | 38,136,000Source | — | 50,954,000Source | 25,391,000Source | 17,384,000Source | 53,981,000Source | 25,952,000Source | 17,928,000Source | 14,983,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 137,700,000Source | 113,200,000Source | 136,400,000Source | 164,300,000Source | — | 181,700,000Source | 117,600,000Source | 110,100,000Source | 205,000,000Source | 88,800,000Source | — | 87,900,000Source |
| Long-term DebtUSD | — | 40,517,000Source | — | — | — | — | — | 40,123,000Source | — | 40,724,000Source | 40,086,000Source | 24,526,000Source |
| Short-term Investments | — | — | — | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -36,591,000Source | -52,103,000Source | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,046,000Source | 1,788,000Source | 9,404,000Source | 7,342,000Source | 5,860,000Source | 6,047,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 1,345,000Source | — | 8,813,000Source | — | -31,000Source | -485,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 454,000Source | — | 1,833,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,846,000Source | 3,173,000Source | 8,422,000Source | -3,158,000Source | 2,283,000Source | 2,599,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -52,116,000Source | -38,676,000Source | -137,509,000Source | -104,771,000Source | -86,460,000Source | -63,673,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -16,015,000Source | — | -9,624,000Source | 59,972,000Source | -44,447,000Source | 66,185,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 28,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 28,692,000Source | 67,427,000Source | 263,305,000Source | 54,782,000Source | 134,194,000Source | 51,784,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | 42,580,000Source | 42,579,000Source | — | 300,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -39,439,000Source | 28,751,000Source | 116,172,000Source | 9,983,000Source | 3,287,000Source | 54,296,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 137,947,000Source | 113,416,000Source | 136,594,000Source | 164,563,000Source | 165,792,000Source | 117,810,000Source | 205,231,000Source | 89,059,000Source | 79,076,000Source | 75,789,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 6,364,000Source | 3,774,000Source | 3,361,000Source | 1,536,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 185,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 3,430,000Source | 3,413,000Source | — | — | 9,405,000Source | 7,342,000Source | 5,860,000Source | 6,047,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 71,000Source | — | — | — | 11,000Source | 11,000Source | 277,000Source | 230,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | -119,000Source | 30,000Source | 29,000Source | -5,000Source | -1,132,000Source | 228,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 279,000Source | — | 698,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 137,700,000Source | 113,200,000Source | 136,400,000Source | 164,300,000Source | 181,700,000Source | 117,600,000Source | 205,000,000Source | 88,800,000Source | — | 87,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | 10,000Source | 30,000Source | 26,000Source | 62,000Source | 118,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | -1,826,000Source | -1,826,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 816,000Source | — | 0Source | 0Source | — | 185,000Source | — | 0Source |
| Investment Income, InterestUSD | — | — | 1,182,000Source | 831,000Source | 1,108,000Source | 822,000Source | 1,297,000Source | 960,000Source | 4,068,000Source | 4,149,000Source | 6,214,000Source | 1,215,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -98,518,000Source | -23,967,000Source | -34,673,000Source | -25,934,000Source | -36,591,000Source | -52,103,000Source | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | -77,000Source | -52,000Source | -110,000Source | -61,000Source | -40,000Source | -203,000Source | -123,000Source | -109,000Source | 47,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 30,162,000Source | 196,976,000Source | 14,221,000Source | 91,420,000Source | 27,354,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | 60,000,000Source | 52,000,000Source | 84,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 42,000Source | 22,000Source | 116,000Source | 241,000Source | 57,000Source | 282,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 11,242,000Source | — | 40,078,000Source | 2,137,000Source | 18,671,000Source | — | 30,914,000Source | 10,000,000Source | — | 2,596,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 21,008,000Source | 12,276,000Source | 27,409,000Source | 20,669,000Source | 22,299,000Source | 15,022,000Source | 81,146,000Source | 43,622,000Source | 30,728,000Source | 24,975,000Source |
| Operating Income (Loss)USD | — | — | -40,715,000Source | -37,030,000Source | -32,710,000Source | -43,764,000Source | -44,897,000Source | -44,174,000Source | -170,129,000Source | -114,956,000Source | -92,084,000Source | -72,937,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | -77,000Source | -52,000Source | -110,000Source | -61,000Source | -40,000Source | -203,000Source | -123,000Source | -109,000Source | 47,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -33,857,000Source | -25,934,000Source | — | — | -209,471,000Source | -130,452,000Source | — | -73,812,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 816,000Source | — | 0Source | 0Source | — | 185,000Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -98,518,000Source | -23,967,000Source | -34,673,000Source | -25,934,000Source | -36,591,000Source | -52,103,000Source | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.35Source | -0.6Source | -0.35Source | -0.39Source | -0.37Source | -0.96Source | -3.02Source | -3.66Source | -3.96Source | -0.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.35Source | -0.6Source | -0.35Source | -0.62Source | -0.46Source | -0.96Source | -3.02Source | -3.66Source | -3.93Source | -0.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 73,157,000Source | 40,258,000Source | 100,116,000Source | 66,143,000Source | 98,292,000Source | 54,173,000Source | 69,309,000Source | 35,713,000Source | 22,054,000Source | 193,654,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 73,157,000Source | 40,258,000Source | 100,116,000Source | 74,037,000Source | 99,148,000Source | 54,173,000Source | 69,309,000Source | 35,713,000Source | 22,054,000Source | 193,654Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 279,000Source | — | 698,000Source | — | — | — |
| Costs and ExpensesUSD | — | — | 51,957,000Source | 37,030,000Source | 72,788,000Source | 45,901,000Source | 63,568,000Source | 44,174,000Source | 201,043,000Source | 124,956,000Source | 92,084,000Source | 75,533,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 185,000Source | — | 0Source |
| Interest ExpenseUSD | — | — | 319,000Source | 1,148,000Source | 360,000Source | 212,000Source | 382,000Source | 192,000Source | 1,138,000Source | 4,562,000Source | 4,139,000Source | 2,137,000Source |
| Investment Income, InterestUSD | — | — | 1,182,000Source | 831,000Source | 1,108,000Source | 822,000Source | 1,297,000Source | 960,000Source | 4,068,000Source | 4,149,000Source | 6,214,000Source | 1,215,000Source |
| Research and Development ExpenseUSD | — | — | 28,989,000Source | 24,754,000Source | 41,338,000Source | 24,786,000Source | 38,218,000Source | 29,152,000Source | 114,599,000Source | 81,334,000Source | 61,356,000Source | 50,558,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Interest Expense (non-operating) | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299873
Filing attachments
tm2628983d2_ex4-8.htm · S-3ASR · 2026-11-05
Exhibit 4.8 VERASTEM, INC. and U.S. Bank TRUST COMPANY, National Association, as Trustee INDENTURE Dated as of, TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. INCORPORATION BY REFER…
Read attachment ↗tm2628982d2_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION NOVEMBER 2026 2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements about, among other things, Verastem Oncology’s (the “Company”) programs an d product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZYNJA® CO - PACK ( avutometinib capsules; defactinib tablets) as a treatment fo…
Read attachment ↗vstm-ex99d1.htm · 10-Q · 2026-11-05
Exhibit 99.1 Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $24.0 million VS-7375 demonstrated robust antitumor activity, encouraging durability, and consistent tolerability, including 41% confirmed ORR in 2L+ PDAC (50% confirmed ORR in 2L PDAC), 43% confirmed ORR in 2L+ NSCLC, and 33% unconfirmed ORR in 3L+ CRC in combination with anti-EGFR therapy, supporting ongoing Phase 2 registration…
Read attachment ↗tm2627537d6_ex4-1.htm · 8-K · 2026-10-14
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE STOCK Company: Verastem, Inc., a Delaware corporation Warrant No. [___] Number of Shares: [___], subject to adjustment Type/Series of Stock: Common Stock, $0.0001 par value per share Issue Date: [●], 2026 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [___] (together with any successor or permitted assignee or transferee of this warrant to purchase stock (this “Warrant”) or of any shares issued upon exercise hereof, “Holder”) i…
Read attachment ↗tm2627537d4_ex99-1.htm · 8-K · 2026-10-14
Exhibit 99.1 Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class investigational oral KRAS G12D (ON/OFF) inhibitor Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and …
Read attachment ↗tm2627537d4_ex99-2.htm · 8-K · 2026-10-14
Exhibit 99.2 VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of patients ongoing >6 months and a 67% landmark 6-month …
Read attachment ↗